- Home
- HMY vs RVMD Comparison
HMY vs RVMD Comparison
Compare HMY & RVMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HMY
- RVMD
- Stock Information
- Founded
- HMY 1950
- RVMD 2014
- Country
- HMY South Africa
- RVMD United States
- Employees
- HMY N/A
- RVMD N/A
- Industry
- HMY Precious Metals
- RVMD Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- HMY Basic Materials
- RVMD Health Care
- Exchange
- HMY Nasdaq
- RVMD Nasdaq
- Market Cap
- HMY 8.7B
- RVMD 7.5B
- IPO Year
- HMY N/A
- RVMD 2020
- Fundamental
- Price
- HMY $15.48
- RVMD $34.70
- Analyst Decision
- HMY Hold
- RVMD Strong Buy
- Analyst Count
- HMY 2
- RVMD 12
- Target Price
- HMY $12.20
- RVMD $69.42
- AVG Volume (30 Days)
- HMY 3.4M
- RVMD 1.7M
- Earning Date
- HMY 01-01-0001
- RVMD 08-06-2025
- Dividend Yield
- HMY 0.90%
- RVMD N/A
- EPS Growth
- HMY 16.30
- RVMD N/A
- EPS
- HMY 0.88
- RVMD N/A
- Revenue
- HMY $3,553,951,394.00
- RVMD N/A
- Revenue This Year
- HMY $22.58
- RVMD N/A
- Revenue Next Year
- HMY $21.51
- RVMD $234.26
- P/E Ratio
- HMY $17.18
- RVMD N/A
- Revenue Growth
- HMY 16.84
- RVMD N/A
- 52 Week Low
- HMY $7.97
- RVMD $29.17
- 52 Week High
- HMY $18.77
- RVMD $62.40
- Technical
- Relative Strength Index (RSI)
- HMY 58.25
- RVMD 35.17
- Support Level
- HMY $13.35
- RVMD $34.00
- Resistance Level
- HMY $16.22
- RVMD $38.60
- Average True Range (ATR)
- HMY 0.42
- RVMD 1.41
- MACD
- HMY 0.18
- RVMD -0.26
- Stochastic Oscillator
- HMY 74.04
- RVMD 14.64
About HMY Harmony Gold Mining Company Limited
Harmony Gold Mining Co Ltd is a gold mining and exploration company having operations in South Africa and Papua New Guinea (PNG). Its projects include Bambanani, Joel, Masimong, Phakisa, Target 1, Tshepong, Unisel, Doornkop, and Kusasalethu. The group's segments are Tshepong Operations, Bambanani, Joel, Doornkop, Moab Khotsong, Hidden Valley, Target 1, Kusasalethu, Masimong, Unisel, and all other surface operations.
About RVMD Revolution Medicines Inc.
Revolution Medicines Inc is a clinical-stage precision oncology company focused on developing novel targeted therapies to inhibit elusive, frontier targets within notorious growth and survival pathways, with particular emphasis on the RAS and mTOR signaling pathways. The company's products includes RMC-4630, a SHP2 inhibitor, RAS(ON) portfolio and SOS1 and 4EBP1/mTORC1 programs.